Breakthrough Solution for Respiratory Infections

Signia Therapeutics proposes a breakthrough strategy for the development of a new generation of antivirals which will target the infected host-cell rather than the virus

About us

Signia Therapeutics is an innovative French start-up from the VirPath laboratory of the University Claude Bernard (Lyon).

SIGNIA Therapeutics proposes a breakthrough strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs or to recycle unused drugs for new antiviral indication against several human respiratory viruses. These antiviral candidates could be directly evaluated in phase II clinical trials and/or quickly available in response to any widespread outbreak for which the medical community and patients have limited options.

Signia Therapeutic’s drug discovery platform has already demonstrated its significant potential with proofs-of-concept already established for several market-approved drugs that were validated for new anti-influenza and anti-MERS-CoV indications.

Learn more

Our solution

To identify and repurpose rapidly, efficiently and at low cost already marketed drugs for new antiviral indication

Host-targeted therapy

By targeting host cellular pathways instead of viral proteins, Signia therapeutics drug candidates achieve broad-spectrum antiviral efficacy and minimize the risk of emergence of drug-resistant viruses

Drug repurposing & recycling

Signia Therapeutics approach offers intrinsic de-risking of drug discovery process, with significant cost and time reduction to validate drug candidates, with rapid transition to phase 2 clinical evaluation.

Innovative approach

Our research strategy is based on the direct exploitation of clinical samples and the characterisation of relevant in vivo transcriptomic signatures of infections, in an innovative bedside-to-bench and bench-to-bedside approach.

Learn more

A major public health issue

Acute respiratory tract infections (ARTI) represent the main cause of acute diseases worldwide and remain the number one cause of deaths in newborns and young children (nearly 2 million deaths/year). Respiratory pathogens constitute a major public health issue and represent a large socio-economic impact.

Up to now, very few efficient vaccines or antiviral candidate treatments have been reported in the medical literature to widely fight against these respiratory pathogens, except for those available against influenza viruses. In an effort to treat these various ARTIs, consumers spend more than $2-3 billion each year, yet new efficient antiviral strategies, less prone to the emergence of resistance, are necessary.

Learn more

Roadmap

Latest developments of Signia Therapeutics

Signia Therapeutic’s drug discovery platform has already demonstrated its significant potential with proofs-of-concept for several FDA-approved drugs that were validated for new anti-influenza and anti-MERS-CoV indications.